Back
Geron Corp (GERN)
BiotechnologyGERN · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$1.36
+7.09%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-0.13
ROE
-27.1%
Gross margin
61.0%
Debt/Equity
0.53x
Revenue growth
30.9%
Geron Corp — company intelligence
Earnings surprises
Q1 2026$-0.01 vs $-0.02 est+52.6%
Q4 2025$-0.02 vs $-0.03 est+38.1%
Q3 2025$-0.03 vs $-0.03 est+11.0%
Q2 2025$-0.02 vs $-0.03 est+35.7%
Analyst consensus · 12 analysts
9 Buy2 Hold1 Sell
Updated Jul 5, 2026
Insider activity · 90 days
6 buys0 sellsnet +3,600,000 shares
Bir Dawn CarterBuy 220,000 · May 20, 2026
McDonald John FBuy 220,000 · May 20, 2026
Molineaux SusanBuy 220,000 · May 20, 2026
Recent SEC filings
4 — Insider transaction reportJul 1, 2026
8-K — Material event reportMay 27, 2026
4 — Insider transaction reportMay 26, 2026
Latest news
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up — SeekingAlpha · 1w ago
Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript — SeekingAlpha · Jun 8, 2026
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Geron Corp
Weekly undervalued picks (like GERN)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.